Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4534192 | 0.83 | HTR2A (0.47) | HTR2AMMP2MMP9OPRM1OPRK1 | |
| SCHEMBL6544207 | 0.77 | OPRM1 (0.44) | HTR2AMMP2MMP9OPRM1OPRK1 | |
| SCHEMBL31504306 | 0.77 | HTR2A (0.41) | HTR2AMMP2MMP9OPRM1OPRK1 | |
| SCHEMBL10046441 | 0.75 | SLC6A4 (0.43) | HTR2ACHRNB2SLC6A2CHRNB4CHRNA3 | |
| SCHEMBL21312268 | 0.75 | OPRM1 (0.42) | HTR2AOPRM1OPRK1OPRL1 | |
| SCHEMBL15995122 | 0.75 | OPRM1 (0.42) | HTR2AOPRM1OPRK1OPRL1 | |
| SCHEMBL15995119 | 0.75 | OPRM1 (0.42) | HTR2AOPRM1OPRK1OPRL1 | |
| SCHEMBL6185187 | 0.73 | MMP2 (0.42) | HTR2AMMP2MMP9OPRM1OPRL1 | |
| SCHEMBL8096947 | 0.73 | MMP2 (0.34) | HTR2AMMP2MMP9OPRM1OPRK1 | |
| SCHEMBL10708233 | 0.73 | OPRM1 (0.41) | HTR2AOPRM1OPRK1OPRL1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104428331-B | Active energy beam polymer resin composition and the laminated body for using the resin combination | 东洋油墨SC控股株式会社 | 2019-02-15 | — | — | CN | disclosed |
| US-9988349-B2 | Direct stereospecific synthesis of unprotected aziridines from olefins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-05 | — | — | US | disclosed |
| US-9988349-B2 | Direct stereospecific synthesis of unprotected aziridines from olefins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-05 | — | — | US | disclosed |
| US-9988349-B2 | Direct stereospecific synthesis of unprotected aziridines from olefins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-05 | — | — | US | disclosed |
| US-20160340305-A1 | DIRECT STEREOSPECIFIC SYNTHESIS OF UNPROTECTED AZIRIDINES FROM OLEFINS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-24 | — | — | US | disclosed |
| US-20160340305-A1 | DIRECT STEREOSPECIFIC SYNTHESIS OF UNPROTECTED AZIRIDINES FROM OLEFINS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-24 | — | — | US | disclosed |
| US-20160340305-A1 | DIRECT STEREOSPECIFIC SYNTHESIS OF UNPROTECTED AZIRIDINES FROM OLEFINS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-24 | — | — | US | disclosed |
| WO-2015103505-A2 | DIRECT STEREOSPECIFIC SYNTHESIS OF UNPROTECTED AZIRIDINES FROM OLEFINS | ESS DANIEL HALSELL (US) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015103505-A2 | DIRECT STEREOSPECIFIC SYNTHESIS OF UNPROTECTED AZIRIDINES FROM OLEFINS | ESS DANIEL HALSELL (US) | 2015-07-09 | — | — | WO | disclosed |
| CN-104428331-A | Active energy ray-polymerizable resin composition and laminate obtained using resin composition | TOYO INK SC HOLDINGS CO LTD | 2015-03-18 | — | — | CN | disclosed |
| EP-2394989-A1 | Method for producing a N-substituted aziridine | BASF SE (DE) | 2011-12-14 | — | — | EP | disclosed |
| EP-2275408-A1 | Method for synthesizing a n-substituted aziridine | BASF SE (DE) | 2011-01-19 | — | — | EP | disclosed |
| US-20100191000-A1 | METHOD FOR SYNTHESIZING AN N-UNSUBSTITUTED OR N-SUBSTITUTED AZIRIDINE | BASF SE (DE) | 2010-07-29 | — | — | US | disclosed |
| CN-101679234-A | Method for synthesizing N-unsubstituted or N-substituted aziridine | BASF SE | 2010-03-24 | — | — | CN | disclosed |
| EP-2160379-A1 | METHOD FOR SYNTHESIZING AN N-UNSUBSTITUTED OR N-SUBSTITUTED AZIRIDINE | BASF SE (DE) | 2010-03-10 | — | — | EP | disclosed |
| WO-2008155355-A1 | METHOD FOR SYNTHESIZING AN N-UNSUBSTITUTED OR N-SUBSTITUTED AZIRIDINE | BASF SE (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100191000-A1 | METHOD FOR SYNTHESIZING AN N-UNSUBSTITUTED OR N-SUBSTITUTED AZIRIDINE | CBR1, CBR3, AOC2 | HTR2A 257/4885MMP2 2750/4885MMP9 3264/4885 |
| US-20160340305-A1 | DIRECT STEREOSPECIFIC SYNTHESIS OF UNPROTECTED AZIRIDINES FROM OLEFINS | AAAS, NISCH, HNMT | HTR2A 62/4885MMP2 4410/4885MMP9 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.